A Comparative Trial of the Safety and Efficacy of 0.1 Percent Pemirolast Potassium Ophthalmic Solution Dosed Twice or Four Times a Day in Patients with Seasonal Allergic Conjunctivitis

Journal of Ocular Pharmacology and Therapeutics

Volumn 20, Issue 2, 2004, Pages 139-150

  Gous, Petrus ^a   Ropo, Auli ^b  

^a Pretoria Eye Institute   (South Africa)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PEMIROLAST;

ADOLESCENT; ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ALLERGY; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPEREMIA; LARYNGITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARYNGITIS; PHOTOPHOBIA; PRICK TEST; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCHOOL CHILD; SCORING SYSTEM; SEASONAL VARIATION; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; CHILD; CONJUNCTIVITIS, ALLERGIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; INSTILLATION, DRUG; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; PYRIDINES; PYRIMIDINONES; SEASONS; TREATMENT OUTCOME;

EID: 1842422519     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/108076804773710812     Document Type: Article

References (20)

1. New drugs for allergic conjunctivitis. Med. Lett. Drugs Ther. 42:39-40, 2000.
2. 2+ mobilization in antigen-stimulated rat basophilic leukemia (RBL-2H3) cells. Arerugi (Allergy, Japan) 43:142-151, 1994.
3. Kawashima, T., Iwamoto, I., Nakagawa, N., Tomioka, H., and Yoshida, S. Inhibitory effect of pemirolast, a novel antiallergic drug, on leukotriene C4 and granule protein release from human eosinophils. Int. Arch. Allergy Immunol. 103:405-409, 1994.
4. Cate, E.A., Rubin, J.M., Rinehart, M., and Graves, A.L. The ocular safety of ALAMAST™ (pemirolast potassium ophthalmic solution) 0.1%, a mast cell stabilizer, in normal healthy children. Invest. Ophthal. Vis. Sci. 40:S914, A4820, 1999.
5. Mundorf, T.K., Lonsdale, J.D., John, T., et al. The ocular efficacy and safety of 0.1% pemirolast potassium ophthalmic solution, a mast cell stabilizer, in patients with seasonal allergic conjunctivitis. Invest. Ophthal. Vis. Sci. 40:S770, A4063, 1999.
6. Graves, A.L., Amdahl, L.D., and Abelson, M.B. The ocular efficacy and safety of ALAMAST™ (pemirolast potassium ophthalmic solution) 0.1%, a mast cell stabilizer, compared to placebo in patients with seasonal allergic conjunctivitis. Poster presentation at XIIth Congress of the European Society of Ophthalmology. Stockholm, Sweden, 1999.
7. Abelson, M.B., Berdy, G.J., Mundorf, T., Amdahl, L.D., and Graves, A.L. The pemirolast study group. Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies. J. Ocul. Pharmacol. Ther. 18:475-488, 2002.
8. Buckley, R.J. Editorial, Diagnosis and treatment of atopic eye disease. Clin. Exp. Allergy 22:887-888, 1992.
9. Ciprandi, G., Buscaglia, S., Cerqueti, P.M., and Canonica, G.W. Drug treatment of allergic conjunctivitis. A review of the evidence. Drugs 43:154-176, 1992.
10. Cochrane, G.M. Compliance and outcomes in patients with asthma. Drugs 52:12-19, 1996.
11. Kubacka, R.T., and Juhl, R.P. Attitudes of patients with hypertension or arthritis toward the frequency of medication administration. Am. J. Hosp. Pharm. 42:2499-2501, 1985.
12. Sato, M., Tsukamoto, H., Sato, E., Unei, H., Kimura, Y., Mishima, H., and Kihira, K. Evaluation and multivariate statistical analysis of factors influencing patient adherence to ophthalmic solutions. Yakugaku Zasshi (J. Pharm. Soc. Jpn.) 121:799-780, 2001.
13. Sclar, D.A., Tartaglione, T.A., and Fine, M.J. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infect. Agents Dis. 3:266-273, 1994.
14. Leino, M., Montan, P., and Nja, F. A double-blind group comparative study of ophthalmic sodium cromoglycate, 2% four times daily and 4% b.i.d., in the treatment of seasonal allergic conjunctivitis. Allergy 49:147-151, 1994.
15. Collum, L.M., Fitzsimon, S., Hillery, M., Collum, A., Power, W.J., Pelikan, Z., and Jenson, J.B. Twice-daily 4% Sodium Cromoglycate vs. 2% Sodium Cromoglycate used four times daily in seasonal (grass pollen) allergic conjunctivitis. Documenta Ophthalmol (Adv. Ophthalmol.) 82:267-277, 1992.
16. Leino, M., Ennevaara, K., Latvala, A.L., Nordgren, P., Posti, A.M., Suves, R., and Takalo, E. Double-blind group comparative study of 2% nedocromil sodium eye drops with 2% sodium cromoglycate and placebo eye drops in the treatment of seasonal allergic conjunctivitis. Clin. Exp. Allergy 22:929-932, 1992.
17. Kitano, S., Kogure, F., Yuasa, T., and Komemushi, S. Clinical effect of 0.1% TBX ophthalmic solution on allergic conjunctivitis: Comparison between 2 × day and 4 × day administration. Folia Ophthalmol. Jpn. 42:201-211, 1991.
18. Shulman, D.G., Amdahl, L., Washington, C., and Graves, A. A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents. Clin. Ther. 24:1996-1106, 2003.
19. Washington, C.L., Shulman, D.G., Amdahl, L.D., and Graves, A.L. The ocular comfort of 0.1% Pemirolast potassium compared to 2% nedocromil sodium. Invest. Ophthal. Vis. Sci. 42:S910, A4892, 2001.
20. Shulman, D.G., Washington, C.L., Amdahl, L.D., and Graves, A.L. An ocular comfort comparison of 0.1% pemirolast potassium ophthalmic solution with 4% cromolyn sodium ophthalmic solution and 0.5% ketorolac tromethamine ophthalmic solution. J. Allergy Clin. Immunol. 107:S215, A709, 2001.